Onconova Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
Due Diligence for Asset Managers
Analyze the public filings of asset managers
Dive into the EDGAR, IAPD, CAFR source data
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Onconova Therapeutics Inc
TickerTRAW
CIK #0001130598
CUSIP68232V884
SectorLife Sciences - Pharmaceutical Preparations
Address375 Pheasant Run, Newtown, PA 18940
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Traws Pharma Inc 2024-04-16 14.0 M Exemption: 506(b) · Duration: One year or less · Commission: $1,039,500 · Revenue: Decline to Disclose
Onconova Therapeutics Inc 2019-06-04 0.5 M Exemption: 506(b) · Minimum: $500,000 · Remaining: $1,500,000 · Duration: One year or less · Revenue: $1 - $1,000,000
CIK Filing 2011 - 2026
[0001130598] 10-K
[0001130598] 10-Q
[0001130598] 3
[0001130598] 4
[0001130598] 8-K
[0001130598] D
[0001130598] SC 13D
[0001130598] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Adage Capital Management LP Traws Pharma Inc [2026-02-12] 0.0
Chernett Jorey Traws Pharma Inc [2026-01-16] 0.0
Adage Capital Management LP Traws Pharma Inc [2025-05-12] 0.0
Ikarian Capital LLC Traws Pharma Inc [2025-02-14] 0.0
Alyeska Investment Group LP Traws Pharma Inc [2025-02-14] 0.0
Ayrton Capital LLC Traws Pharma Inc [2025-02-13] 0.0
Perceptive Advisors LLC Traws Pharma Inc [2025-01-08] 0.0
OrbiMed Advisors LLC Traws Pharma Inc [2024-09-23] 19.9
Viriom Inc Traws Pharma Inc [2024-04-08] 6.5
CVI Investments Inc Onconova Therapeutics Inc [2021-10-01] 5.7
Lincoln Park Capital Fund LLC Onconova Therapeutics Inc [2021-01-08] 6.52
Armistice Capital LLC Onconova Therapeutics Inc [2020-01-10] 4.99
Armistice Capital LLC Onconova Therapeutics Inc [2019-12-19] 4.99
Intracoastal Capital LLC Onconova Therapeutics Inc [2019-12-02] 4.99
Point72 Asset Management LP Onconova Therapeutics Inc [2019-11-26] 0.99
Sabby Management LLC Onconova Therapeutics Inc [2019-09-27] 2.52
Armistice Capital LLC Onconova Therapeutics Inc [2019-09-26] 4.99
EcoR1 Capital LLC Onconova Therapeutics Inc [2018-05-07] 0.99
Armistice Capital LLC Onconova Therapeutics Inc [2018-02-20] 0.0
683 Capital Management LLC Onconova Therapeutics Inc [2018-02-16] 21.8
Sabby Management LLC Onconova Therapeutics Inc [2017-05-01] 7.61
Reddy E Premkumar Onconova Therapeutics Inc [2016-08-19] 5.8
Tyndall Capital Partners L P Onconova Therapeutics Inc [2016-08-18] 13.5
Baxalta Inc Onconova Therapeutics Inc [2016-02-12] 0.6
Reddy E Premkumar Onconova Therapeutics Inc [2016-02-11] 5.84
Frigate Ventures LP Onconova Therapeutics Inc [2016-01-13] 7.1
Baxalta Inc Onconova Therapeutics Inc [2015-05-11] 12.0
Reddy E Premkumar Onconova Therapeutics Inc [2015-02-11] 6.32
Reddy E Premkumar Onconova Therapeutics Inc [2014-02-14] 6.35
Baxter International Inc Onconova Therapeutics Inc [2013-08-09] 12.2
Hoffman Michael B Onconova Therapeutics Inc [2013-08-02] 21.4
Form 3/4/5 Filer 2011 - 2026
OrbiMed Advisors LLC
OrbiMed Capital GP VIII LLC
Traws Pharma Inc
Parker Charles Nolan
Dukes Iain D
Stover Jack E
Redfield Robert
Leaman John Harold
Cautreels Werner
Pauza Charles David
Savchuk Nikolay
Clarke Trafford
Shoemaker Mary Teresa
TPAV LLC
Guerin Mark Patrick
Brennan Nora
Greenwood Luba
Viriom Inc
Fruchtman Steven M
Moyo Victor M
Atadja Peter
Mehta Viren
Groopman Jerome
Marino James J
Gelder Mark S MD
OLER Abraham N
Hoffman Michael B
Reddy E Premkumar
Woodman Richard Charles
Maniar Manoj
Tyndall Capital Partners L P
Armistice Capital Master Fund Ltd
Boyd Steven
Armistice Capital LLC
Zweiman Ari
683 Capital Partners LP
683 Capital Management LLC
Kumar Ramesh
Bienen Henry S
McKearn Thomas J
Bansal Ajay
Vanlent Anne
Baxter Healthcare SA
Baxalta GmbH
Baxalta Inc
Michael & Jane Hoffman 2013 Descendants
Altland James
Baxter International Inc
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Stover Jack E
Stock Option (right to buy) · derivative
2026-03-08 Grant 33,435 $0.00
Redfield Robert
Stock Option (right to buy) · derivative
2026-03-08 Grant 108,854 $0.00
Clarke Trafford
Stock Option (right to buy) · derivative
2026-03-08 Grant 33,435 $0.00
Shoemaker Mary Teresa
Stock Option (right to buy) · derivative
2026-03-08 Grant 33,435 $0.00
Pauza Charles David
Stock Option (right to buy) · derivative
2026-03-08 Grant 118,367 $0.00
Dukes Iain D
Stock Option (right to buy) · derivative
2026-03-08 Grant 231,336 $0.00
Leaman John Harold
Stock Option (right to buy) · derivative
2026-03-08 Grant 33,435 $0.00
Savchuk Nikolay
Stock Option (right to buy) · derivative
2026-03-08 Grant 96,899 $0.00
Cautreels Werner
Stock Option (right to buy) · derivative
2026-03-08 Grant 31,258 $0.00
Cautreels Werner
Common Stock
2025-12-12 Grant 4,874 $0.00
Shoemaker Mary Teresa
Common Stock
2025-12-12 Grant 6,157 $0.00
Pauza Charles David
Stock Option (right to purchase) · derivative
2025-12-12 Grant 73,886 $0.00
Leaman John Harold
Common Stock
2025-12-12 Grant 4,058 $0.00
Stover Jack E
Common Stock
2025-12-12 Grant 6,157 $0.00
Stover Jack E
Stock Option (right to purchase) · derivative
2025-12-12 Grant 24,629 $0.00
Cautreels Werner
Stock Option (right to purchase) · derivative
2025-12-12 Grant 19,496 $0.00
Redfield Robert
Stock Option (right to purchase) · derivative
2025-12-12 Grant 65,676 $0.00
Clarke Trafford
Stock Option (right to purchase) · derivative
2025-12-12 Grant 24,629 $0.00
Savchuk Nikolay
Common Stock
2025-12-12 Grant 16,419 $0.00
Shoemaker Mary Teresa
Stock Option (right to purchase) · derivative
2025-12-12 Grant 24,629 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 28 3,619,802
2025-12-31 22 3,418,593
2025-09-30 18 1,304,595
2025-06-30 20 1,263,487
2025-03-31 20 1,732,327
2024-12-31 19 1,170,406
2024-09-30 12 646,363
Form 13F Holdings
Firm Period DFND Voting Shares
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com